Spectral AI Announces FDA De Novo Clearance for DeepView System
Spectral AI has secured FDA de novo classification, now authorized to launch sales in the U.S., bolstered by $86.6M in Project BioShield funding and plans for global expansion.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day